Skip to main content
Joseph Maakaron, MD, Oncology, Minneapolis, MN

JosephMaakaronMD

Oncology Minneapolis, MN

Hematologic Oncology

Assistant Professor of Medicine

Dr. Maakaron is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Maakaron's full profile

Already have an account?

  • Office

    909 Fulton St SE
    MMC 2121BD
    Minneapolis, MN 55455
    Phone+1 612-676-4200
    Fax+1 612-676-4004

Summary

  • I am a hematologist and medical oncologist specializing in treatment of blood cancers (leukemias and lymphomas) with bone marrow transplantation and cellular therapies.

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2016 - 2019
  • Indiana University School of Medicine
    Indiana University School of MedicineResidency, Internal Medicine, 2013 - 2016
  • American University of Beirut Faculty of Medicine
    American University of Beirut Faculty of MedicineClass of 2011, MD, AOA

Certifications & Licensure

  • MN State Medical License
    MN State Medical License Active through 2026
  • OH State Medical License
    OH State Medical License 2016 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Alpha Omega Alpha 2011

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...
    Joseph Maakaron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgki... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Professional Memberships

Other Languages

  • Arabic